{"id":68167,"date":"2019-07-29T12:53:28","date_gmt":"2019-07-29T04:53:28","guid":{"rendered":"http:\/\/facfox.com\/news\/aerospace\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics.3dm"},"modified":"2019-07-29T12:53:28","modified_gmt":"2019-07-29T04:53:28","slug":"3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics","status":"publish","type":"post","link":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/","title":{"rendered":"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics"},"content":{"rendered":"<div id=\"dpsp-content-top\" class=\"dpsp-content-wrapper dpsp-shape-rectangular dpsp-size-medium dpsp-has-spacing dpsp-has-buttons-count dpsp-show-on-mobile dpsp-button-style-1\">\n<ul class=\"dpsp-networks-btns-wrapper dpsp-networks-btns-content dpsp-networks-btns-share dpsp-column-auto\">\n<li><span class=\"dpsp-network-icon\"><\/span><span class=\"dpsp-network-label-wrapper\"><\/span><\/li>\n<li><span class=\"dpsp-network-icon\"><\/span><span class=\"dpsp-network-label-wrapper\"><\/span><\/li>\n<li><span class=\"dpsp-network-icon\"><\/span><span class=\"dpsp-network-label-wrapper\"><\/span><\/li>\n<li><span class=\"dpsp-network-icon\"><\/span><span class=\"dpsp-network-label-wrapper\"><\/span><\/li>\n<\/ul>\n<\/div>\n<p><span style=\"font-weight: 400;\">Kentucky-based 3D bioprinting company <\/span><span style=\"font-weight: 400;\">Koligo Therapeutics<\/span><span style=\"font-weight: 400;\"> (ASX:KOL) is due to list on the <\/span><span style=\"font-weight: 400;\">Australian Securities Exchange<\/span><span style=\"font-weight: 400;\"> at the end of March through an <\/span><span style=\"font-weight: 400;\">Initial Public Offering<\/span><span style=\"font-weight: 400;\"> (IPO). <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Koligo is hoping to raise up to AUD$7m at 20c a share from the IPO, establishing a market value of approximately AUD$22m. Koligo will use the funds raised through the IPO to expand its manufacturing capacity and drive sales into targeted hospitals, so that medical treatments can utilise Koligo technology. Furthermore, Koligo is looking to take advantage of opportunities for international growth, and to develop its patented 3D-V technology platform and product pipeline. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Matthew Lehman, CEO of Koligo, explains, \u201cOur listing on the ASX will accelerate Koligo\u2019s growth and improve our ability to make a real difference in patients\u2019 lives who suffer these debilitating conditions. The local market understands the value these companies provide. <\/span><span style=\"font-weight: 400;\">We are heartened by the success of other regenerative medicine and cell therapy companies on the ASX, such as Exopharm, Polynovo and Cynata.\u201d<\/span><\/p>\n<p><iframe src=\"https:\/\/www.youtube.com\/embed\/YNrInbxagrU\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p><b>Engineering tissue and cell transplantation with 3D bioprinting<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Koligo\u2019s 3D-V bioprinting platform is intended to develop and improve its regenerative medicine products and engineer cell and tissue transplantation with 3D bioprinting technology. The 3D bioprinted products are planned for commercial release and will be used to treat serious health conditions and disorders such as pancreatitis, type 1 diabetes, liver failure and more. An example of Koligo&#8217;s 3D bioprinting processes includes Stylescel-L, where a 3D bioprinted spheroid is injected into patients to allow better oxygen and blood flow.  Lehman adds: <\/span><\/p>\n<blockquote>\n<p><span style=\"font-weight: 400;\">\u201cKoligo will transform human cell and tissue transplant with our 3D-V bio-printing. We will create 3D biodegrable bio-printed spheroids which contain a patient\u2019s stromal vascular fraction cells and\/ or micro vascular fragments and pancreas islets [&#8230;] These spheroid \u2018scaffolds\u2019 allow improved function of the cell or tissue after transplant and safely biodegrade.\u201d<\/span><\/p>\n<\/blockquote>\n<p><span style=\"font-weight: 400;\">Koligo is also committed to the wide distribution of pancreatic islets, which are the cells that produce insulin in the pancreas. The company distributes the islets as part of its Kyslecel product, to help treat pancreatitis, a condition resulting in the inflammation of the pancreas. Koligo partners with hospitals to remove and transfer a patient\u2019s pancreas to its FDA-registered labs. The pancreatic islets are then preserved into \u2018Kyslecel\u2019, and sent back to hospitals to be implanted into the patient\u2019s liver, in order to regulate blood sugar levels and treat the condition. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">The company is at revenue stage with its Kyslecel product, where it is qualified for sale in the United States. Koligo estimates Kyslecel to have an annual addressable market of AUD$300m in the U.S., with the product already having generated AUD$1.6m revenue for Koligo in the first 14 months of sale from a limited number of hospital customers. By mid-2019, Koligo aim to release Kyslecel V2.0, which will maintain an improved shelf-life, allowing extended transport times for further regions and possible international distribution. With Kyslecel V2.0, Koligo estimates the US market size to be AUD$600m per year, and the company has plans to enter the Indian and Chinese markets as well. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u201cThe location of the Koligo lab is key as Louisville, Kentucky is also the home of the UPS Worldport hub with 318 flights daily and the capability for critical shipments of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCTPs). Based on initial success of Kyslecel\u2122, Koligo will scale production and distribution to deliver patients access to this procedure at more hospitals across the United States.\u201d<\/span><\/p>\n<figure id=\"attachment_150784\" style=\"width: 750px\" class=\"wp-caption aligncenter\"><img fetchpriority=\"high\" decoding=\"async\" class=\"size-full wp-image-150784\" src=\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png\" alt=\"A step by step process detailing the stages of the Stylescel-L product. Image via Koligo.\" width=\"750\" height=\"492\" srcset=\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png 750w, https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs-200x131.png 200w, https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs-500x328.png 500w\" sizes=\"(max-width: 750px) 100vw, 750px\" \/><figcaption class=\"wp-caption-text\">A step by step process detailing the stages of the Stylescel-L product. Image via Koligo.<\/figcaption><\/figure>\n<p><b>A step forward for 3D bioprinting<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Koligo\u2019s IPO and listing on the ASX represents the latest advancement for the commercialization of 3D bioprinting. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Chicago-based <\/span><span style=\"font-weight: 400;\">BIOLIFE4D<\/span><span style=\"font-weight: 400;\">, another biotechnology company that filed an <\/span><span style=\"font-weight: 400;\">IPO of $50 million<\/span><span style=\"font-weight: 400;\"> in September 2017, successfully demonstrated the ability to <\/span><span style=\"font-weight: 400;\">3D print human heart tissue<\/span><span style=\"font-weight: 400;\"> in June 2018. The company eventually hopes to be <\/span><span style=\"font-weight: 400;\">3D printing valves<\/span><span style=\"font-weight: 400;\">, blood vessels, miniature organs and a full human heart. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Furthermore, California-based 3D bioprinting company <\/span><span style=\"font-weight: 400;\">Organovo Holdings Inc<\/span><span style=\"font-weight: 400;\"> is due to meet with the Food and Drug Administration (FDA) this year on its development of <\/span><span style=\"font-weight: 400;\">3D bioprinted tissues<\/span><span style=\"font-weight: 400;\"> for the treatment of liver diseases. In 2016 the company previously suggests that its <\/span><span style=\"font-weight: 400;\">3D bioprinted liver tissue<\/span><span style=\"font-weight: 400;\"> could make it to the FDA by 2019. <\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Subscribe to the <\/span><\/i><i><span style=\"font-weight: 400;\"><a href=\"\/service\/3d-printing\"> Industry newsletter<\/span><\/i><i><span style=\"font-weight: 400;\"> for the latest news in additive manufacturing. You can also keep connected by following us on <\/span><\/i><i><span style=\"font-weight: 400;\">Twitter<\/span><\/i><i><span style=\"font-weight: 400;\"> and liking us on <\/span><\/i><i><span style=\"font-weight: 400;\">Facebook.<\/span><\/i><\/p>\n<p><i><span style=\"font-weight: 400;\">Looking for a career in additive manufacturing? Visit <\/span><\/i><i><span style=\"font-weight: 400;\"><a href=\"\/service\/3d-printing\"> Jobs<\/span><\/i><i><span style=\"font-weight: 400;\"> for a selection of roles in the industry.<\/span><\/i><\/p>\n<p><em>Featured image shows Koligo&#8217;s 3D-V technology. Screengrab via Koligo. <\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an Initial Public Offering (IPO). Koligo is hoping to raise up to AUD$7m at 20c a share from the IPO, establishing a market value of approximately AUD$22m. Koligo will use the funds raised [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":182392,"comment_status":"open","ping_status":"close","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"fifu_image_url":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png","fifu_image_alt":"","footnotes":""},"categories":[53],"tags":[169,170],"class_list":["post-68167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aerospace","tag-3dprint","tag-3dprinting"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics - FacFox News<\/title>\n<meta name=\"description\" content=\"Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an\" \/>\n<meta property=\"og:url\" content=\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"FacFox News\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-29T04:53:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png\" \/>\n<meta name=\"author\" content=\"edi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"edi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/\"},\"author\":{\"name\":\"edi\",\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/person\/30c6618bf20fcdd6af222ac673dfd857\"},\"headline\":\"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics\",\"datePublished\":\"2019-07-29T04:53:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/\"},\"wordCount\":781,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/facfox.com\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png\",\"keywords\":[\"3dprint\",\"3dprinting\"],\"articleSection\":[\"Aerospace\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/\",\"url\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/\",\"name\":\"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics - FacFox News\",\"isPartOf\":{\"@id\":\"https:\/\/facfox.com\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png\",\"datePublished\":\"2019-07-29T04:53:28+00:00\",\"description\":\"Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an\",\"breadcrumb\":{\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage\",\"url\":\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png\",\"contentUrl\":\"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/facfox.com\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/facfox.com\/news\/#website\",\"url\":\"https:\/\/facfox.com\/news\/\",\"name\":\"FacFox News\",\"description\":\"News and Insights of 3D Printing and Manufacturing\",\"publisher\":{\"@id\":\"https:\/\/facfox.com\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/facfox.com\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/facfox.com\/news\/#organization\",\"name\":\"FacFox News\",\"url\":\"https:\/\/facfox.com\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png\",\"contentUrl\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png\",\"width\":200,\"height\":55,\"caption\":\"FacFox News\"},\"image\":{\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/person\/30c6618bf20fcdd6af222ac673dfd857\",\"name\":\"edi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f64f2d9574372e5e27ea0251aee0b353f2ac65df22b55672ae03a41a20cbbbd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f64f2d9574372e5e27ea0251aee0b353f2ac65df22b55672ae03a41a20cbbbd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f64f2d9574372e5e27ea0251aee0b353f2ac65df22b55672ae03a41a20cbbbd?s=96&d=mm&r=g\",\"caption\":\"edi\"},\"sameAs\":[\"https:\/\/facfox.com\/news\"],\"url\":\"https:\/\/facfox.com\/news\/author\/edi\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics - FacFox News","description":"Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics","og_description":"Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an","og_url":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/","og_site_name":"FacFox News","article_published_time":"2019-07-29T04:53:28+00:00","og_image":[{"url":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png","type":"","width":"","height":""}],"author":"edi","twitter_card":"summary_large_image","twitter_image":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png","twitter_misc":{"Written by":"edi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#article","isPartOf":{"@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/"},"author":{"name":"edi","@id":"https:\/\/facfox.com\/news\/#\/schema\/person\/30c6618bf20fcdd6af222ac673dfd857"},"headline":"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics","datePublished":"2019-07-29T04:53:28+00:00","mainEntityOfPage":{"@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/"},"wordCount":781,"commentCount":0,"publisher":{"@id":"https:\/\/facfox.com\/news\/#organization"},"image":{"@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png","keywords":["3dprint","3dprinting"],"articleSection":["Aerospace"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/","url":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/","name":"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics - FacFox News","isPartOf":{"@id":"https:\/\/facfox.com\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png","datePublished":"2019-07-29T04:53:28+00:00","description":"Kentucky-based 3D bioprinting company Koligo Therapeutics (ASX:KOL) is due to list on the Australian Securities Exchange at the end of March through an","breadcrumb":{"@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#primaryimage","url":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png","contentUrl":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png"},{"@type":"BreadcrumbList","@id":"https:\/\/facfox.com\/news\/3d-bioprinting-will-enter-australian-securities-exchange-with-koligo-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/facfox.com\/news\/"},{"@type":"ListItem","position":2,"name":"3D bioprinting will enter Australian Securities Exchange with Koligo Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/facfox.com\/news\/#website","url":"https:\/\/facfox.com\/news\/","name":"FacFox News","description":"News and Insights of 3D Printing and Manufacturing","publisher":{"@id":"https:\/\/facfox.com\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/facfox.com\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/facfox.com\/news\/#organization","name":"FacFox News","url":"https:\/\/facfox.com\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/","url":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png","contentUrl":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png","width":200,"height":55,"caption":"FacFox News"},"image":{"@id":"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/facfox.com\/news\/#\/schema\/person\/30c6618bf20fcdd6af222ac673dfd857","name":"edi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7f64f2d9574372e5e27ea0251aee0b353f2ac65df22b55672ae03a41a20cbbbd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f64f2d9574372e5e27ea0251aee0b353f2ac65df22b55672ae03a41a20cbbbd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f64f2d9574372e5e27ea0251aee0b353f2ac65df22b55672ae03a41a20cbbbd?s=96&d=mm&r=g","caption":"edi"},"sameAs":["https:\/\/facfox.com\/news"],"url":"https:\/\/facfox.com\/news\/author\/edi\/"}]}},"fifu_image_url":"https:\/\/3dprintingindustry.com\/wp-content\/uploads\/2019\/03\/fsfsffs.png","_links":{"self":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/posts\/68167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/comments?post=68167"}],"version-history":[{"count":0,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/posts\/68167\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/media\/182392"}],"wp:attachment":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/media?parent=68167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/categories?post=68167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/tags?post=68167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}